While the MoCRA Act provided the FDA with a once-in-a-lifetime chance to set matters right and take federal responsibility for full industry regulation, the agency chose not to, and prolonged the chaotic mess our industry has dealt with for so long.
Image by Orhan Çam at Adobe Stock
Editor's note: This commentary from Matthew Zoeller, applications director for specialty chemicals at 3V Sigma USA, critiques the U.S. Food and Drug Administration's (FDA's) approach to cosmetics regulation through the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). It highlights the FDA's "lethargy" in the "face of realpolitik" and calls out state control over the FDA, among other issues. While it does not necessarily reflect the opinions of C&T, we offer it for your consideration and investigation.
!['The most polluting industries, pharmaceuticals and cosmetics, will be required to pay at least [80%] of the cost for micropollutant removal...'](https://img.cosmeticsandtoiletries.com/files/base/allured/all/image/2024/01/scientist_water_monitor_sample_pollutionAdobeStock_297782139.65ba74e958d97.png?auto=format%2Ccompress&fit=crop&h=191&q=70&rect=0%2C151%2C2179%2C1227&w=340)